利伐沙班：在心血管疾病管理中的扩展作用——文献综述。
Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review.
机构信息
University of Arizona, College of Medicine, Tucson, AZ, USA.
出版信息
Cardiovasc Ther. 2021 Jan 8;2021:8886210. doi: 10.1155/2021/8886210. eCollection 2021.
Abstract
Direct oral anticoagulants (DOACs) are widely used for the prevention of stroke in nonvalvular atrial fibrillation, treatment of deep venous thrombosis and pulmonary embolism, and as prophylaxis after hip and knee surgery after approval by the Food and Drug Administration. In the last decade, DOACs were studied for various indications; this review is focused on rivaroxaban, a factor Xa inhibitor, which is used in an expanded evidence-based fashion for coronary artery disease, peripheral artery disease, heart failure, malignancy, and prophylaxis of deep venous thrombosis in acute medical illnesses.
摘要
直接口服抗凝剂（DOACs）在获得食品药品监督管理局批准后，被广泛用于预防非瓣膜性心房颤动的中风、深静脉血栓和肺栓塞的治疗，以及髋关节和膝关节手术后的预防。在过去十年中，DOACs 已被用于各种适应症的研究；本综述重点介绍了利伐沙班，一种 Xa 因子抑制剂，它被以扩展的基于证据的方式用于冠状动脉疾病、外周动脉疾病、心力衰竭、恶性肿瘤以及急性内科疾病的深静脉血栓预防。
相似文献
1
Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review.
Cardiovasc Ther. 2021 Jan 8;2021:8886210. doi: 10.1155/2021/8886210. eCollection 2021.
2
Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan.
J Stroke Cerebrovasc Dis. 2020 Apr;29(4):104584. doi: 10.1016/j.jstrokecerebrovasdis.2019.104584. Epub 2020 Jan 23.
3
Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study.
J Stroke Cerebrovasc Dis. 2016 Jun;25(6):1342-8. doi: 10.1016/j.jstrokecerebrovasdis.2016.01.035. Epub 2016 Mar 14.
4
The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
J Cardiovasc Pharmacol Ther. 2014 Nov;19(6):526-32. doi: 10.1177/1074248414525505. Epub 2014 Mar 21.
5
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
J Am Heart Assoc. 2016 Mar 8;5(3):e002197. doi: 10.1161/JAHA.115.002197.
6
Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
Ann Pharmacother. 2020 Apr;54(4):344-350. doi: 10.1177/1060028019886092. Epub 2019 Oct 31.
7
Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Eur J Epidemiol. 2019 Feb;34(2):173-190. doi: 10.1007/s10654-018-0415-7. Epub 2018 Jun 8.
8
Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
BMJ Open. 2018 Jun 22;8(6):e020286. doi: 10.1136/bmjopen-2017-020286.
9
Intracardiac Thrombus Following Rivaroxaban Treatment in a Patient with Atrial Fibrillation Associated with Rheumatic Heart Disease.
J Stroke Cerebrovasc Dis. 2019 Nov;28(11):104325. doi: 10.1016/j.jstrokecerebrovasdis.2019.104325. Epub 2019 Aug 16.
10
Rivaroxaban (Xarelto) plus aspirin for secondary prevention of cardiovascular events.
Med Lett Drugs Ther. 2018 Dec 3;60(1561):196-197.
引用本文的文献
1
Rivaroxaban alleviates hepatic sinusoidal obstruction syndrome in mice by modulating the gut microbiota and inhibiting the PI3K/Akt signaling pathway.
Front Microbiol. 2025 Aug 21;16:1607131. doi: 10.3389/fmicb.2025.1607131. eCollection 2025.
2
Beyond Anticoagulation: A Comprehensive Review of Non-Vitamin K Oral Anticoagulants (NOACs) in Inflammation and Protease-Activated Receptor Signaling.
Int J Mol Sci. 2024 Aug 10;25(16):8727. doi: 10.3390/ijms25168727.
3
Efficacy and Safety of Different Doses of Rivaroxaban and Risk Factors for Bleeding in Elderly Patients with Venous Thromboembolism: A Real-World, Multicenter, Observational, Cohort Study.
Adv Ther. 2024 Jan;41(1):391-412. doi: 10.1007/s12325-023-02717-5. Epub 2023 Nov 21.
4
evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban.
Front Pharmacol. 2023 Oct 4;14:1263975. doi: 10.3389/fphar.2023.1263975. eCollection 2023.
5
Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data.
Eur J Clin Pharmacol. 2023 Dec;79(12):1675-1685. doi: 10.1007/s00228-023-03572-7. Epub 2023 Oct 10.
6
XGBoost-based machine learning test improves the accuracy of hemorrhage prediction among geriatric patients with long-term administration of rivaroxaban.
BMC Geriatr. 2023 Jul 10;23(1):418. doi: 10.1186/s12877-023-04049-z.
7
Risk Factors for Rivaroxaban-Related Bleeding Events-Possible Role of Pharmacogenetics: Case Series.
Pharmacy (Basel). 2023 Feb 5;11(1):29. doi: 10.3390/pharmacy11010029.
8
Effective Formation of New C(sp )-S Bonds via Photoactivation of Alkylamine-based Electron Donor-Acceptor Complexes.
Chemistry. 2023 Jan 27;29(6):e202203353. doi: 10.1002/chem.202203353. Epub 2022 Dec 5.
9
Analysis of the Preventive Action of Rivaroxaban against Lower Extremity Deep Venous Thrombosis in Patients after Laparoscopic Radical Gastrectomy.
Comput Math Methods Med. 2022 Sep 10;2022:7140066. doi: 10.1155/2022/7140066. eCollection 2022.
10
Evaluation of Herb-Drug Interaction Between Danshen and Rivaroxaban in Rat and Human Liver Microsomes.
Front Pharmacol. 2022 Jul 19;13:950525. doi: 10.3389/fphar.2022.950525. eCollection 2022.
本文引用的文献
1
Benefit and risk of adding rivaroxaban in patients with coronary artery disease: A systematic review and meta-analysis.
Clin Cardiol. 2021 Jan;44(1):20-26. doi: 10.1002/clc.23514. Epub 2020 Nov 21.
2
Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials.
Cardiovasc Ther. 2020 Jun 23;2020:3057168. doi: 10.1155/2020/3057168. eCollection 2020.
3
Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi.
JAMA Cardiol. 2020 Jun 1;5(6):685-692. doi: 10.1001/jamacardio.2020.0652.
4
New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients.
J Clin Med. 2020 Apr 2;9(4):1002. doi: 10.3390/jcm9041002.
5
Oral Anticoagulation and Cardiovascular Outcomes in Patients With Atrial Fibrillation and End-Stage Renal Disease.
J Am Coll Cardiol. 2020 Mar 24;75(11):1299-1308. doi: 10.1016/j.jacc.2020.01.019.
6
Left Atrial Appendage Closure in Patients With Intracranial Hemorrhage and Nonvalvular Atrial Fibrillation.
J Stroke Cerebrovasc Dis. 2020 Apr;29(4):104685. doi: 10.1016/j.jstrokecerebrovasdis.2020.104685. Epub 2020 Feb 11.
7
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.
N Engl J Med. 2020 Jan 9;382(2):120-129. doi: 10.1056/NEJMoa1911425. Epub 2019 Nov 16.
8
Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial.
Ann Intern Med. 2019 Nov 19;171(10):685-694. doi: 10.7326/M19-0291. Epub 2019 Oct 15.
9
Stroke Prevention in Atrial Fibrillation: The Role of Oral Anticoagulation.
Med Clin North Am. 2019 Sep;103(5):847-862. doi: 10.1016/j.mcna.2019.05.006.
10
A comparison of anticoagulation, antiplatelet, and placebo treatment for patients with heart failure reduced ejection fraction in sinus rhythm: a systematic review and meta-analysis.
Heart Fail Rev. 2020 Mar;25(2):207-216. doi: 10.1007/s10741-019-09818-w.
Zotero 插件